Pharmacological Treatment and Current Management of Peripheral Artery Disease

被引:87
作者
Bonaca, Marc P.
Creager, Mark A.
机构
[1] Brigham & Womens Hosp, Vasc Med Sect, Cardiovasc Div, Boston, MA 02115 USA
[2] Harvard Univ, Sch Med, Boston, MA USA
关键词
medical therapy; peripheral artery disease; THROMBIN-RECEPTOR ANTAGONIST; PROTEASE-ACTIVATED RECEPTORS; CARDIOVASCULAR EVENT RATES; ASSOCIATION TASK-FORCE; HIGH-DOSE ATORVASTATIN; INTERMITTENT CLAUDICATION; SECONDARY PREVENTION; SMOKING-CESSATION; VASCULAR-DISEASE; CONTROLLED-TRIAL;
D O I
10.1161/CIRCRESAHA.114.303505
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Patients with peripheral artery disease (PAD) are at heightened risk of both systemic cardiovascular adverse events, as well as limb-related morbidity. The optimal management of patients with PAD requires a comprehensive treatment strategy incorporating both lifestyle changes, including smoking cessation and exercise, as well as optimal medical therapy. Pharmacological therapies for patients with PAD are targeted both at modifying broad risk factors for major adverse cardiovascular events, as well as reducing limb-related morbidity. Observational data suggest that indicated pharmacological treatments are greatly underutilized in PAD, underscoring the need for improvements in patient identification and care delivery. Ongoing trials of novel therapies in patients with PAD will further inform pharmacological strategies to reduce both systemic cardiovascular risk and limb-related morbidity.
引用
收藏
页码:1579 / 1598
页数:20
相关论文
共 130 条
[1]   Fate of individuals with ischemic amputations in the REACH Registry: Three-year cardiovascular and limb-related outcomes [J].
Abola, Maria Teresa B. ;
Bhatt, Deepak L. ;
Duval, Sue ;
Cacoub, Patrice P. ;
Baumgartner, Iris ;
Keo, Hong ;
Creager, Mark A. ;
Brennan, Danielle M. ;
Steg, Ph. Gabriel ;
Hirsch, Alan T. .
ATHEROSCLEROSIS, 2012, 221 (02) :527-535
[2]   RETRACTED: Effect of Ramipril on Walking Times and Quality of Life Among Patients With Peripheral Artery Disease and Intermittent Claudication A Randomized Controlled Trial (Retracted Article) [J].
Ahimastos, Anna A. ;
Walker, Philip J. ;
Askew, Christopher ;
Leicht, Anthony ;
Pappas, Elise ;
Blombery, Peter ;
Reid, Christopher M. ;
Golledge, Jonathan ;
Kingwell, Bronwyn A. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2013, 309 (05) :453-460
[3]  
Anand S, 2007, NEW ENGL J MED, V357, P217
[4]  
[Anonymous], 2013, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD003075.pub3
[5]  
[Anonymous], NEW ENGL J MED
[6]  
[Anonymous], 2014, CIRCULATION, DOI DOI 10.1161/01.cir.0000441139.02102.80
[7]  
[Anonymous], PROD INF ZONTIVITY T
[8]   Effect of Simvastatin versus placebo on treadmill exercise time until the onset of intermittent claudication in older patients with peripheral arterial disease at six months and at one year after treatment [J].
Aronow, WS ;
Nayak, D ;
Woodworth, S ;
Ahn, C .
AMERICAN JOURNAL OF CARDIOLOGY, 2003, 92 (06) :711-712
[9]   Lipid-lowering for peripheral arterial disease of the lower limb [J].
Aung, P. P. ;
Maxwell, H. G. ;
Jepson, R. G. ;
Price, J. F. ;
Leng, G. C. .
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2007, (04)
[10]  
Baigent C, 2002, BMJ-BRIT MED J, V324, P71, DOI 10.1136/bmj.324.7329.71